Symphogen AS - Strategic SWOT Analysis Review

Date: November 29, 2017
Pages: 26
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SFB44A161F4EN
Leaflet:

Download PDF Leaflet

Symphogen AS - Strategic SWOT Analysis Review
Symphogen AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

Symphogen A/S (Symphogen) is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics to enhance the lives of patients with cancer and other diseases with significant unmet medical needs. Its product pipeline provides novel approaches to a wide range of cancer types including metastatic colorectal cancer (mCRC), glioblastoma (GBM), solid tumor malignancies and MET-amplified solid tumors and partner targets. It has collaborations for the development of antibody therapeutics in immuno-oncology with Shire and infectious disease area with Genentech. Symphogen has offices in Denmark and New Jersey, the US.

Symphogen AS Key Recent Developments

Sep 14,2016: Symphogen Names New Chief Financial Officer
Aug 18,2016: Symphogen’s Founding CEO Kirsten Drejer Steps Down and Becomes Executive Director
May 11,2016: Symphogen Announces the Appointment of Jeffrey H. Buchalter and Christoffer Soderberg as Non-Executive Directors

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

Symphogen A/S - Key Facts
Symphogen A/S - Key Employees
Symphogen A/S - Key Employee Biographies
Symphogen A/S - Major Products and Services
Symphogen A/S - History
Symphogen A/S - Company Statement
Symphogen A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Symphogen A/S - Business Description
Symphogen A/S - Corporate Strategy
Symphogen A/S - SWOT Analysis
SWOT Analysis - Overview
Symphogen A/S - Strengths
Symphogen A/S - Weaknesses
Symphogen A/S - Opportunities
Symphogen A/S - Threats
Symphogen A/S - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Symphogen A/S, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Sep 14, 2016: Symphogen Names New Chief Financial Officer
Aug 18, 2016: Symphogen’s Founding CEO Kirsten Drejer Steps Down and Becomes Executive Director
May 11, 2016: Symphogen Announces the Appointment of Jeffrey H. Buchalter and Christoffer Soderberg as Non-Executive Directors

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Symphogen A/S, Key Facts
Symphogen A/S, Key Employees
Symphogen A/S, Key Employee Biographies
Symphogen A/S, Major Products and Services
Symphogen A/S, History
Symphogen A/S, Subsidiaries
Symphogen A/S, Key Competitors
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Symphogen A/S, Recent Deals Summary

LIST OF FIGURES

Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Symphogen A/S, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Zealand Pharma AS
Roche Innovation Center Copenhagen A/S
Nuevolution A/S
Mundipharma A/S
MedAnnex Ltd
Lead Pharma Holding BV
CytoVac AS
Bifodan A/S
Bavarian Nordic A/S
Affitech A/S
2cureX ApS
Skip to top


Ask Your Question

Symphogen AS - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: